PTU - Polskie Towarzystwo Urologiczne
list of articles:

Intravesical chemotherapy of superficial bladder cancer
Article published in Urologia Polska 2002/55/1.

authors

Anna Ko這dziej, Janusz Dembowski
Klinika Urologii Akademii Medycznej we Wroc豉wiu Kierownik kliniki: prof, dr hab. Jerzy Lorenz

keywords

bladder, bladder carcinoma, intravesical chemotherapy

summary

Superficial bladder cancer has a high tendency to recur and in significant subset of patients, to progress. Analysis of the clinical risk factors of superficial bladder cancer, such as grade, stage, size, recurrence rate, and multifocality is crucial to predict the course of the disease. The field of topical therapy can roughly be divided into the chemotherapeutic and immunotherapeulic approaches. Chemotherapeutic agents have been used in the therapeutic ablation of existing or residual tumours and in prophylaxis against their recurrence. Monofocal stage pTaGl primary tumours require no prophylactic treatment on account of their low risk of recurrence and progression; at most, an immediate postoperative one-time instillation of cytostatics to reduce the adhesion of released tumor cells is indicated. Because of the increased tendency to progression patients with pTlG3 represents a high-risk group, required immunotherapy. For all other superficial bladder tumors lying between these two extremes, the time elapsing after TURBT until the next recurrence can at least be prolonged through intravesical chemoprophyla-xis.

references

  1. 1. Hcnncy NM, Ahmed S, Flanagan MJ, Hawkins IR: Superficial bladder cancer: Progression et recurrence. J. Urol 1983; 130; 1083-1086.
  2. 2. Cookson MS, Herr HW, Zng ZE Soloway S, Sogani P, Fair W: The treated history of high risk superfial badder cancer: 15 year outcome. J Urol 1997; 158; 62-67.
  3. 3. Herr HW: Tumor progression and survival in patients with T1G3 bladder tumors: 15 year outcome. Br J Urol 1997; 80; 162-765.
  4. 4. Kurth KH, Denis L, Bouffioux C, Sylwester R, Debrune FM, Pavonc-Macaluso M, Oocstcrlinck W: Factors affecting recurrence and progression in superficial bladder tumors. Eur J Cancer 1995; 31A (11); 1840-1846.
  5. 5. Allard P, Bernard P, Fradet Y, Tetu B: The early clinical course ofpiimaiy Ta and Tl bladder cancer: a proposed prognostic index. Br J Urol 1998; 81; 692-698.
  6. 6. Ko這dziej A, Kasprzak J: Prognostic Factors in the Bladder TC in: Recent Advances in the Knowledge of Cancer. Med Univ of Wroclaw; 2000; 181.
  7. 7. Tribukait B: Flow cytometry in assesing the genitourinaiy neoplasm. Word J Urol 1987; 5; 108-120.
  8. 8. Kurth K, Denis L, Ten Kate FJW, Sylwester R, Boul\\\'ioux C, Debruyne FJM, Ooeslerlink W: Prognostic factors in superficial bladder cancer. Problems in Urology; 6; 471-483.
  9. 9. Kurth KH: Diagnosis et treatment of superficial transitional cell carcinoma of the bladder: facts et perspectives. Eur Urol 1997; 3 (suppl. I); 10-19.
  10. 10. Ko這dziej A, Lorenz J: The predictive value of flow cytometiy analysis in bladder cancer-study comparing paired specimens from bladder washing and tissue. Brit J Urol 1997; sup. 80 (2); 28.
  11. 11. Schmidbaucr CP, Porpaczy P, Rameis H: Absoiption ofdoxoni-bicin hydrochloride and mitomycin C after instillation into non-infected and infected bladders of dogs. J Urol 1984; 131: 818-821.
  12. 12. Dalton JT, Wientjes MG, Badalament RA, Drago JR: Phanna-cokinetics of intravesical mitomycin C in superficial bladder cancer patients. Cancer Res 1991; 51; 5144-5152.
  13. 13. Wientjes GM, Dalton JT, Badalament RA, Drago JR: Bladder wall penetration of intravesical mitomycin C\\\' in dogs. Cancer Res 51; 4347-4354.
  14. 14. Bono AV, Hall RR, Denis L, Lovisolo JA, Sylvester R: Chemo-resection in Ta-Tl bladder cancer. Members of the EORTC Geni-to-Vrinary Group. Eur Urol 1996; 29; 385-390.
  15. 15. Pawinski A, Sylvester R, Kurth KH, Bouffioux C, van der Mc-ijden A, Parmar MK i wsp:/l combined analysis of EORTC and MRC randomised clinical trials for the prophylactic treatment of stage TaTlbladder cancer. European Organisation for Research and Treatment of Cancer Genitourinary Trad Cancer Cooperative Group and the Medical Research Council Working Party on superficial bladder Cancer. J Urol 1996; 156; 1934-1940.
  16. 16. Oesterlinck W, Kurth KH, Schroeder F: A prospective EORTC--GU group randomized trial comparing transurethral resection followed by single intravesical instillation ofepirubicin or water in single stage Ta, Tl papillary carcinoma of the bladder. J Urol 1993; 149; 749-52.
  17. 17. Bouffioux Ch, Kurth K, Bono A: Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 EORTC randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short term versus long term treatment. J Urol 1995; 153; 934-941.
  18. 18. Lamm DL: Maintenance versus no-maintenance BCG-immun-otherapy of superficial bladder cancer. J Urol 1992; 147, 4; 274a.
  19. 19. Lamm DL, Brent A, Blumenslain JD et al: Maintenance Bacillus Calmette-Guerin Immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomised Southwest Oncology Group Study. J Urol 2000; 163; 1124-1129.
  20. 20. Braake M, Loertzer H, Horsch R, Keller H: Long-term results of intravesical BCG therapy for stage Tl superficial bladder cancer. Urology 2000; 55; 673-678.
  21. 21. Ko這dziej A, Lorenz J, Dembowski J, Zdrojowy R, Niezgoda T, Wo幡iak P: BCG therapy of patients with superficial bladder cancer- early results of maintenance schedule. Brit J Urol 2000 International; 86, Supp. 3; 218-258.
  22. 22. Ali-al. -Dein B, Nabeeh A, Ismail E, Ghoneim M: Sequential BCG and epimbicin versus BCG alone for superficial bladder tumors: a randomized prospective study. J Urol 1999; 162; 339-342.
  23. 23. Kaasincn E, Rintala E, Pere A: Weekly mitomycin C followed by monthly BCG or alternating monthly inteiferon-a2B and BCG for prophylaxis of recurrent papillary superficial bladder carcinoma. J Urol 2000; 164; 47-52.
  24. 24. Colombo R, Da Pozzo L, Lev A: Local microwave hypertermia and intravesical chemotherapy as bladder sparing treatment for select multifocal and unresectable superficial bladder tumors. J Urol 1998; 159; 783-787.

correspondence

Anna Ko這dziej
Katedra i Klinika Urologii AM
pi I Maja ti
50-043 Wroclaw